Candriam S.C.A. Has $38.57 Million Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Candriam S.C.A. lessened its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 0.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 280,154 shares of the biotechnology company’s stock after selling 2,177 shares during the period. Candriam S.C.A.’s holdings in Ascendis Pharma A/S were worth $38,569,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Loomis Sayles & Co. L P increased its holdings in shares of Ascendis Pharma A/S by 35.3% in the 3rd quarter. Loomis Sayles & Co. L P now owns 184,623 shares of the biotechnology company’s stock valued at $27,566,000 after purchasing an additional 48,120 shares during the period. Valence8 US LP acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at about $685,000. Rice Hall James & Associates LLC increased its holdings in shares of Ascendis Pharma A/S by 2.0% in the 4th quarter. Rice Hall James & Associates LLC now owns 163,888 shares of the biotechnology company’s stock valued at $22,562,000 after purchasing an additional 3,274 shares during the period. Nomura Asset Management Co. Ltd. increased its holdings in shares of Ascendis Pharma A/S by 42.5% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company’s stock valued at $2,688,000 after purchasing an additional 5,371 shares during the period. Finally, Maven Securities LTD acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at about $7,466,000.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ASND. TD Cowen dropped their target price on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Wedbush reissued an “outperform” rating and issued a $181.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. The Goldman Sachs Group boosted their price target on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Morgan Stanley set a $180.00 price target on Ascendis Pharma A/S in a research note on Tuesday, February 18th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $202.36.

Ascendis Pharma A/S Stock Up 3.3 %

Shares of ASND stock opened at $155.86 on Thursday. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $158.00. The firm has a market cap of $9.46 billion, a PE ratio of -21.95 and a beta of 0.64. The stock has a 50 day moving average of $136.59 and a 200-day moving average of $134.09.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.64. As a group, equities analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.